Image source: Getty Images.
Continue Reading Below
Shares of tiny immunotherapy developer Agenus Inc. (NASDAQ: AGEN) tumbled 44.7% in October, according to data from S&P Global Market Intelligence. A larger-than-expected loss in its third-quarter earnings report overshadowed news that its partner,GlaxoSmithKline (NYSE: GSK), submitted an application for the two companies' partnered shingles vaccine.
Agenus Inc.'s third-quarter loss spiked 209% over the previous year period to $40.8 million, catching analysts off guard. No investors want to see their company's loss widen, but the results aren't nearly as ugly as they appear to be on the surface. Non-cash expenses, stemming mostly from existing asset value adjustments, increased by $22.7 million in the third quarter compared with the same period last year. As the term "non-cash" suggests, this sort of expense has more to do with accounting protocol than it does the core of the business.
What didn't help Agenus' stock price last month was a case of election-season jitters for the overall biotech space. The industry-tracking iShares Nasdaq Biotechnology ETF sank 11.5% last month. Even news of an on-schedule application submission from GlaxoSmithKline for a shingles vaccine Agenus is partnered on wasn't enough to perk up the latter company's stock with the sector-wide dark cloud overhead.
If Glaxo's Shingrix earns a widely expected approval, Agenus is entitled to at least 10 years of royalties from sales expected to reach about $1 billion annually at its peak. If approved, Shingrix will challengeMerck & Co.'s Zostavax, which generated $749 million in sales last year. The two vaccines haven't been tested head-to-head, but Shingrix showed some impressive results in studies supporting its application that could quite feasibly help it gain traction in the commercial setting.
During the third quarter, Agenus also noted a $4.9 million increase in expenses related to advancing itsclinical-stage pipeline. The biotech has a cancer vaccine in mid-stage clinical development, and a GITR agonist in early-stage clinical studies. Expenses related to these programs are split between Agenus and its partner Incyte.
Agenus is also advancing a CTLA-4 antagonistthrough early-stage clinical studies with intentions of combining it with an anti-PD1 drug, which will probably be Keytruda through an existing collaboration with Merck.Yervoy fromBristol-Myers Squibbis another CTLA-4 antagonist, which recently earned approval for treatment in combination with anti-PD1 Opdivo for treatment of advanced skin cancer. Bristol's combo provides a yardstick to measure success for a potential combination study with Agenus' candidate of the same class. With so many irons in the fire, and a market cap of around $345 million at recent prices, my hunch is that Agenus is seeing some overblown pessimism.
A secret billion-dollar stock opportunity The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.